4.5 Review

Epigenetics: A primer for clinicians

期刊

BLOOD REVIEWS
卷 30, 期 4, 页码 285-295

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2016.02.002

关键词

5-Methylcytosine (5mC); Cytosine phospho-guanine (CpG); DNA methyltransferases (DNMTs); 5-Hydroxymethylcytosine (5HmC); DNMT inhibitor (DNMTi); Hypomethylating agent (HMA); Ten eleven translocation (TET)

资金

  1. NIH [5T32CA009072-39]
  2. Roswell Park Alliance Foundation
  3. Roswell Park Cancer Institute
  4. RPCI's Cancer Center Support Grant from the NCI [P30CA016056]
  5. Sklarow Memorial Trust
  6. Astex Pharmaceuticals

向作者/读者索取更多资源

With recent advances in cellular biology, we now appreciate that modifications to DNA and histones can have a profound impact on transcription and function, even in the absence of changes to DNA sequence. These modifications, now commonly referred to as epigenetic alterations, have changed how we understand cell behavior, reprogramming and differentiation and have provided significant insight into the mechanisms underlying cardnogenesis. Epigenetic alterations, to this point, are largely identified by changes in DNA methylation and hydroxymethylation as well as methylation, acetylation, and phosphorylation of histone tails. These modifications enable significant flexibility in gene expression, rather than just turning genes ON or OFF. Herein we describe the epigenetic landscape in the regulation of gene expression with a particular focus on interrogating DNA methylation in myeloid malignancy. (C) 2016 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据